Systematic Review of Genetic Polymorphisms Associated with Acute Pain and Relevant Acute Toxicities Induced by Radiotherapy for Head and Neck Cancer.

Vivian Salama^{1*}, Yimin Geng², Jillian Rigert¹, Clifton D. Fuller¹, Amy C. Moreno¹, Sanjay Shete³, Cielito C. Reyes-Gibby^{4*}.

¹ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

² Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

⁴ Department of Emergency Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

*Corresponding authors

Vivian Salama; <u>vsalama@mdanderson.org</u> Cielito C. Reyes-Gibby; <u>creyes@mdanderson.org</u>

Abstract:

Background/objective: Pain is the most common acute toxicity following radiation therapy (RT) for head and neck cancer (HNC). The multifactorial origin of radiotherapy-induced pain makes it highly challenging to manage in HNC patients. Multiple studies have been conducted to identify different germline genetic variants associated with cancer pain, however few of them focused on RT-induced acute pain. In this systematic review, we summarize potential mechanisms of acute pain after radiotherapy in HNC focusing on oral cavity/oropharyngeal cancer and identify genetic variants associated with radiotherapy-induced acute pain and other relevant acute toxicities.

Methods: A comprehensive search of Ovid Medline, EMBASE and Web of Science databases using concepts and terms including "Variants", "Polymorphisms", "Radiotherapy", "Acute pain", "Acute toxicity" published up to February 28, 2022 was performed by two reviewers. Review articles and citations were reviewed manually. The reported SNPs associated with RT-induced acute pain and toxicities were reported, and the molecular function of the associated genes and pathways were described based on genetic annotation using The Human Gene Database; GeneCards.

Results: A total of 386 articles were identified electronically and an additional 8 articles were included after manual search. 39 articles were finally included. 51 variants were associated with 40 genes, of which 30 % had function in DNA damage response and repair, 25% in inflammatory and immune response, 17.5 % in cell death or cell cycle, and were associated with RT-inflammatory pain and acute mucositis or dermatitis. 4 variants in 4 genes were associated with neuropathy and neuropathic pain. 13 variants in 10 genes and were associated with RT-induced mixed types of post-RT-pain.

Conclusion: Different types of pain develop after RT, including inflammatory pain (acute mucositis and acute skin reaction); neuropathic pain; nociceptive pain; and mixed oral pain. Genetic variants involved in DNA damage response and repair, cell death, inflammation and neuropathic pathways may affect pain presentation post-RT. These variants could be used for acute pain prediction and personalized pain management in HNC patients receiving RT.

Keywords Genetic variants, Polymorphisms, Radiation Pain, Radiation Mucositis, Radiation Dermatitis. Head and Neck Cancer

Introduction:

Head and neck squamous cell carcinoma (HNSCC) are composed of a heterogenous mix of malignant epithelial cancers that arises from the oral cavity, pharynx or larynx. Oral cavity and oropharyngeal (OC/OPC) squamous cell carcinoma, afflicted more than 54,000 patients in the U.S, in 2022 ¹.Management of OC/OPC is a stage-dependent multimodality approach that entails surgery, chemotherapy, and radiotherapy. Radiotherapy (RT) is a cornerstone for the management of OC/OPC patients. RT, especially after application of the novel RT techniques, has a favorable impact on the overall survival rates ². Despite improvement in survival rates, various significant acute and sometimes chronic or permanent toxicities are reported during and after RT. RT-attributable toxicities, including mucositis, dermatitis and dysphagia, have significant negative impacts on patients' quality of life (QOL) and may rarely even lead to death ³⁻⁵.

Oral/throat pain, the most common radiation-attributable acute toxicity during and after locoregional RT of OC/OPC, is associated with increase in analgesics use ⁶. About 68-86% of OC/OPC patients and about one-third of HNC patients present to the emergency department with uncontrolled pain ⁷⁻¹¹. The control of RT-induced acute pain is challenging because of the complex nature and multiple mechanisms of pain in these patients. Baseline pain and associated RT toxicities such as mucositis, dermatitis, neuropathy, and dysphagia are considered the most common etiologies of RT-induced pain. In addition, pain due to surgery and/or chemotherapy are also observed in these patients ¹²⁻¹⁴. Most clinicians will prescribe opioids to OC/OPC patients during cancer therapy, with 15-40% of patients dependent on opioids for several months post therapy ¹⁵⁻¹⁷. The optimal use of opioids is a major clinical challenge. While trying not to undertreat patients with severe pain, potential overuse of opioids may negatively impact the health status and the quality of life of patients. Furthermore, for a subset of patients, the prolonged use of opioids increases the risk for drug abuse and addiction, which may negatively impact the QOL and increase the potential for overdose and death ¹⁸.

The mechanism of radiotherapy-induced cell death and normal tissue toxicities:

<u>Radiation therapy</u> is a group of ionizing energy beams that induce DNA damage in cells, cancer cells being most susceptible due to their characteristic of rapid cell division. Direct DNA damage is induced by ionizing radiation to DNA, inducing DNA breaks (single-strand breaks (SSBs), double strand breaks (DSBs)) and covalent crosslinking of the complementary DNA strands ^{19, 20}. Indirect DNA damage occurs through RT-induced generation of free radicals. For instance, reactive oxygen species (ROS) are produced by the interaction of ionizing radiation with the water molecules ²¹. After RT, the impairment of DNA repair mechanisms in cancer cells in addition to the accumulation of intracellular ROS induces cell injury and apoptosis, necrosis and cellular senescence ²²⁻²⁵. However, normal neighboring healthy tissues will also be exposed to ionizing radiation, inducing normal cell injury and maybe cell death despite the lower doses of radiation exposure. Normal tissue damage induces toxicities such as oral mucositis, dermatitis, and neuropathy leading to aggravation of RT-induced acute pain. The severity of RT-induced toxicities and pain is dependent on the total dose, fractions and the duration of radiation delivered to normal tissue in addition to the variation in tissue tolerance to radiation ^{26, 27}.

Types and potential mechanisms of radiotherapy induced acute pain in OC/OPC patients:

Adequate management of acute pain in OC/OPC patients during RT requires good understanding of the different types and mechanisms of RT-induced pain. Three main types of RT-induced acute pain have been identified in HNC patients receiving RT ²⁸⁻³⁰:

- 1. Inflammatory pain
- 2. Nociceptive pain

3. Neuropathic pain



Figure 1: Types and potential mechanisms of radiotherapy induced acute pain. 1- Radiotherapy in head and neck cancer induces DNA damage of cancer cells and normal neighbor cells and release of reactive oxygen species (ROS). DNA damage induces activation of DNA repair mechanisms which is impaired in cancer cells. Impairment of repair of damaged DNA induces activation of cell death through stimulation of apoptosis processes. Normal tissue death induces mucositis and dermatitis causing **inflammatory pain. 2-** Radiotherapy induces activation of immune responses and inflammatory cells which release inflammatory mediators such as cytokines and chemokines inducing inflammatory pain. Furthermore, these inflammatory mediators act as noxious stimuli, stimulating nociceptors to induce **nociceptive pain. 3-** Radiotherapy induces direct mechanical and thermal damage in addition of change in the microenvironment creating an acidic pH and increase in the adenosine triphosphate (ATP), and release of bradykinin and substance P which act as nociceptors stimuli inducing nociceptive pain. Radiotherapy induces direct nerve injury and inflammation of peripheral nervous system, and fibrosis in the connective tissue can also induce **neuropathic pain**.

1. Inflammatory pain:

Inflammatory pain, the most common type of RT-induced acute pain in HNC, is caused by activation of inflammatory and immune cells in response to tissue injury and infections induced by RT ^{21, 31}. Inflammatory and immune cells in addition to RT-induced damaged cells release inflammatory mediators such as pro-inflammatory cytokines: interleukin (IL)-1 β , IL-6, NF-kB, prostaglandins (PG), and tumor necrosis factor- α (TNF- α) ^{21, 32, 33}. These cytokines induce more recruitment of immune and inflammatory cells, inducing more damage of tissues ³⁴. Oral/pharyngeal mucositis and neck dermatitis are the most common inflammatory reactions induced by RT ^{21, 33, 35, 36}. Different signaling pathways involved in RT-induced mucositis and

dermatitis have been identified, and they may contribute to RT-induced inflammatory pain, such as: nuclear factor- κ B (NF- κ B) signaling which upregulates other pathways such as COX2 pathway and downstream tyrosine kinase receptor pathways (e.g. PI3K/AKT signaling and MAPK signaling). Other signaling pathways such as DNA damage checkpoints, cell cycle pathways, WNT/B-catenin and integrin signaling, VEGF signaling, glutamate receptor signaling and IL-6 signaling, have also been identified in correlation with RT-induced mucositis ^{36, 37}.

2. Nociceptive pain:

Nociceptive pain is caused by direct damage to non-neural tissue, often caused by an external injury which stimulates nociceptive receptors ³⁰. Noxious stimuli are released from either damaged cancer, normal cells or from inflammatory/immune cells recruited after RT ³⁸. Noxious stimuli activate the peripheral sensory neurons through stimulation of afferent sensory neurons which transmit the action potential to neuronal bodies where calcium influx occurs, leading to the release of neurotransmitters (e.g.: substance-P, glutamate, γ -aminobutyric acid (GABA), adenosine triphosphate (ATP), glycine, dopamine, norepinephrine, nitric oxide, and serotonin) which bind to the post-synaptic membrane receptors. The signal then reaches the second order neuron and is transmitted to the somatosensory cortex of the brain where the pain is perceived ³⁹⁻⁴³. The trigeminal nerves and the facial nerves (CN VII) play important roles in pain perception in the head and neck ⁴⁴. RT-damaged cells and infiltrating immune cells release multiple noxious stimuli. Cytokines and inflammatory mediators released from infiltrating immune cells such as IL-1, TNF- α and IL-6 induce nociceptor sensitization. In addition, the acidic pH of the tumor microenvironment and extracellular ATP act as noxious stimuli to nociceptors at the cancer site ⁴⁵.

3. Neuropathic pain:

Neuropathic pain is caused by damage to nerves or nervous system ⁴⁶. RT directly injures the somatosensory nervous system promoting pain signal transmission and peripheral neuropathic pain. RT induces DNA damage which induces apoptosis. Apoptosis is induced through p53 activation which activates the cascade to execute cell death ^{47, 48}. Endothelial cell death reduces blood flow to peripheral nerves, including damage and eventual neuronal fibrosis. Furthermore, ionizing radiation and ROS released after RT, cause neuronal cell stress and direct nerve damage. In RT of HNC, the brachial plexus are the neural tissues at high risk of damage. Overexpression of p53 induces apoptosis of neurons after radiation exposure ⁴⁹. Furthermore, RT induces inflammation and infiltration by immune cells, resulting in immune-mediated peripheral neuropathy. Chronic inflammation in the nervous system microenvironment promotes neuron loss with fibrosis, resulting in chronic neuropathic pain ⁵⁰.

Genetic variants associated with radiotherapy induced acute pain:

Advances in molecular and genetic technologies have motivated researchers and scientists toward exploring the human genome and analyzing genetic variations and their correlations with different diseases and treatment outcome.

RT-induced acute pain presents a significant morbidity burden on OC/OPC patients receiving RT and drastically reduces patients' quality of life. In an effort to better predict and optimize pain management approaches, various cellular and molecular approaches have been widely explored recently to identify the genomic biomarkers for patients vulnerable to develop RT-induced pain, and the influence of these genetic variants on pain modulation and analgesic response ^{51, 52}. The advanced technologies in human genome sequencing allowed deep understanding of the genetic variations and mutations related to cancer treatment associated pain. Single nucleotide polymorphisms (SNPs) are the most common DNA sequence variations.

These genetic polymorphisms are stable markers and easily and reliably assayed to explore the extent to which genetic variation might prove useful in identifying patients with cancer at high-risk of pain development and their response to pain therapies ⁵³. Likewise, these candidate SNPs could be used in building robust predictive models for pre-treatment prediction of acute as well as chronic toxicities for personalized management and precision medicine ⁵⁴.

Given the multifactorial and complex etiology of RT-induced pain in HNC patients, the challenges in managing RT-associated pain, and the adverse impact of pain on patients' quality of life, the aim of this literature review is to identify predictive genetic variants and pathways associated with RT-induced pain and related phenotypes. This synthesis of the current literature will use provide the basis to develop predictive models of RT-induced acute pain to assist with personalized analgesic therapy.

Materials and Methods:

Search Strategies:

We conducted a systematic search of databases including Ovid MEDLINE, Ovid Embase, and Clarivate Analytics Web of Science, for publications in English language from the inception of databases to February 28, 2022. The following concepts were searched using subject headings and free text keywords as needed, "radiotherapy", "radiation therapy", "pain", "neuropathy", "analgesics", "opioid", "acute toxicity", "mucositis", "dermatitis", "single nucleotide polymorphism", "genetic variation", "genetic variability", and "genetic predisposition" etc. The terms were combined using AND/OR Boolean Operators. Animal studies, in vitro studies, and conference abstracts were removed from the search result. Handsearching of journals and publisher databases and manually checking the reference lists of journal articles were also conducted to supplement the electronic database search. The complete electronic database search strategies were detailed in Supplementary Tables S1–S3.

Inclusion criteria:

The included studies met all of the following inclusion criteria: 1) articles published in English, 2) human studies in any type of cancers, 3) genetic polymorphisms reported to be significantly associated with RT-induced pain in different phenotypes (Inflammatory [Mucositis, dermatitis], neuropathy, nociceptive pain or mixed oral/throat pain). We included variants associated with our phenotypes in any type of cancer, for comprehensive search intent and to identify new SNPs identified in other cancers that need more focus in HNC.

Exclusion criteria:

Articles were excluded if they met any of the following criteria: 1) non-genetic article or no genetic association study, 2) not radiotherapy induced pain or toxicity, 3) meta-analysis, or review article, 4) articles written in languages other than English, 5) clinical trials, 6) non-human study, or not blood or buccal DNA or 7) Other unrelated phenotypes like dysphagia, gastrointestinal toxicities (e.g. diarrhea).

Functional annotation:

Manual functional annotation of the identified genes was done using GeneCards database. The function of each gene was assigned according to the most common functional pathway annotated in the GenCards and the relevant studies published online. ^{55, 56} We divided the collected variants and genes into three groups: 1) variants associated with RT-induced inflammatory pain including; RT-induced acute toxicities; acute mucositis and acute dermatitis (or acute skin reaction), 2)

variants associated with other types of RT-induced acute pain (including post RT-pain, post-RT throat/mouth/neck pain and neuropathic pain/neuropathy)



Flow Chart of systematic review of SNPs associated Radiation-induced acute pain and relevant acute toxicities.

Results:

1- Variants associated with radiotherapy induced inflammatory pain:

Mucositis and acute skin reactions are the most common acute reactions reported following RT. 51 variants in 40 genes were associated with radiotherapy induced inflammatory pain and acute

reactions including mucositis or dermatitis. (Table 1). Table 2 shows the biological functions and pathways of the genes associated with RT-induced acute mucositis and acute skin reaction. We found that 12 genes (32%) were involved in DNA damage and DNA repair pathways. 10 genes (19.5%) were involved in inflammatory pathways and immune systems, 7 genes (19.5%) were regulating cell death, apoptosis, autophagy or cell cycle pathways, 6 genes (17%) were involved in metabolisms and microenvironment functional pathways, 5 genes were functionally involved in other functional pathways. (Figure 2, table 2)



Table 1: Summary of literature search of variants associated with radiotherapy induced acute inflammatory pain.

SNP	Gene	Function/Pathway	Phenotype	Sample/cancer	Number of patients	Author /year
rs28419191 rs10875554	STING1	Inflammation/ immune system	Mucositis	Blood DNA/ HNC	1780	Schack et.al. / 2022. ⁵⁷
rs1131769	DNAJC18	Chaperone molecules protecting other cellular proteins	Mucositis	Blood DNA/ HNC	1780	Schack et.al. / 2022. ⁵⁷
rs1265081	CCHCR1	keratinocyte proliferation or differentiation/ EGFR	Mucositis	Blood DNA/ HNC	500	Li et al./ 2021. ⁵⁸
rs3135001	HLA-DQB1	MHC class II, immune system	Mucositis	Blood DNA/ HNC	500	Li et.al./ 2021. ⁵⁸
rs117157809	TNKS	Telomere capping and maintenance and telomerase activity	Mucositis	Blood DNA/ NPC	1467	Yang et.al. / 2020. ⁵⁹

rs1799964	TNF-α	Proinflammatory cytokines	Mucositis	Blood DNA/ HNC	62	Mlak et.al. / 2020. 60
rs25487	XRCC1	DNA repair	Radiation- induced toxic reactions	Blood DNA/ NSCLC	486	Yang et.al. / 2020. 61
rs3218556	XRCC2	DNA repair	Radiation- induced toxic reactions	Blood DNA/ NSCLC	486	Yang et.al. / 2020. 61
rs13181	XPD	DNA repair	Radiation- induced toxic reactions	Blood DNA/ NSCLC	486	Yang et.al. / 2020. 61
rs10898880	ATG16L2	Autophagy	Mucositis	Blood DNA/ NPC	468	Yang et.al. / 2019. ⁶²
rs10514231	ATG10	Autophagy	Mucositis	Blood DNA/ NPC	468	Yang et.al. / 2019. ⁶²
rs25487	XRCC1	DNA repair	Mucositis	Blood DNA/ OPC	179	Gupta et.al. / 2019. ⁶³
rs4149570	TNFRSF1A	TNF-α Proinflammatory	Mucositis	Blood DNA/ HNC	58	Brzozowska et.al. / 2018. ⁶⁴
rs1629816	GHRL	Modifier of proinflammatory cytokine activity	Mucositis	Blood DNA/ HNC	65	Brzozowska et.al. / 2018. 65
rs4855883	APEH	Proteasome degradation	Mucositis	Blood DNA/ HNC	62	Brzozowska et.al. / 2018. 66
rs9344	CCND1	Cell cycle. NF-кB signaling	Mucositis	Blood DNA/ NPC	154	Guo et.al. / 2017. ⁶⁷
rs9344	CCND1	Cell cycle and NF- ĸB signaling	Mucositis	Blood DNA/ NPC	174	Wang et.al. / 2017. ⁶⁸

rs1800541	EDN1	Angiogenesis- related genes	Mucositis	Blood DNA/NPC	180	Ma et.al. / 2017. ⁶⁹
rs11081899	ZNF24	DNA replication, and DNA damage response, NF-kB activation, tumor progression and angiogenesis	Mucositis	Blood DNA / NPC	33	Le et.al. / 2017. 70
rs375557	GSK3β	Wnt/β-catenin pathway	Mucositis and	Blood DNA/ NPC	188	Yu et.al. / 2016.
rs454886	APC		dermatitis			
rs1805794	NBN	DNA damage response, DNA repair	Mucositis	Blood DNA/ HNC	183	Venkatesh et.al. / 2014. ⁷²
rs132788	Ku70	DNA repair	Mucositis	Blood DNA/ NPC	120	Ren et.al. / 2014. 73
rs25487	XRCC1	DNA repair	Mucositis and dermatitis	Blood DNA/ NPC	114	Li et.al. / 2013. ⁷⁴
rs25487	XRCC1	DNA repair	Mucositis	Blood DNA/ HNC	101	Pratesi et.al. / 2011. ⁷⁵
rs1799782	XRCC1	DNA repair	Acute radiation- induced toxicity (mucositis and skin)	Blood DNA/ laryngeal squamous cell carcinoma	150	Raturi et.al. / 2020. ⁷⁶
rs61915066	АТМ	DNA damage response (DDR)	Early Adverse Skin Reactions post- RT	Blood DNA/ Breast cancer	416	Lee et.al. / 2020.
rs11220184	CHEK1	DNA damage response (DDR)	Early Adverse Skin Reactions post- RT	Blood DNA/ Breast cancer	416	Lee et.al. / 2020.
rs302877 rs405684	RAD51C	DNA damage response (DDR)	Early Adverse Skin Reactions post- RT	Blood DNA/ Breast cancer	416	Lee et.al. / 2020.

rs2241714 rs4803455	TGFB1	Cell growth, differentiation and apoptosis	Early Adverse Skin Reactions post- RT	Blood DNA/ Breast cancer	416	Lee et.al. / 2020.
rs60152947 rs10404465 rs1799786	ERCC2	DNA damage response (DDR)	Early Adverse Skin Reactions post- RT	Blood DNA/ Breast cancer	416	Lee et.al. / 2020.
rs631134	PLA2G2F/ IIF	Acute inflammation	Acute radiotherap y skin erythema	Blood DNA/ Breast cancer	1,838	Rattay et.al. / 2020. ⁷⁸
rs12554549	PTPN3	Cell growth, differentiation, mitotic cycle, and oncogenic transformation	Acute radiotherap y skin ulceration	Blood DNA/ Breast cancer	1,838	Rattay et.al. / 2020. ⁷⁸
rs1233255	PMS1	DNA repair	Dermatitis	Blood DNA/ Rectal cancer	365	Yang et.al. / 2019. ⁷⁹
rs2040639	XRCC2	DNA repair	Acute radiation skin reactions	Blood DNA/ Breast cancer	119	Oliva et.al. / 2018. ⁸⁰
rs2069705	IFNG	Immune response	Acute radiation skin reactions	Blood DNA/ Breast cancer	119	Oliva et.al. / 2018. ⁸⁰
rs8193	CD44	Immune response	RT-induced adverse skin reactions	Blood DNA/ Breast cancer	135	Mumbrekar et.al. / 2017. ⁸¹
rs2282367	MAT1A	Oxidative stress, MAPK, ERK and genomic instability	RT-induced adverse skin reactions	Blood DNA/ Breast cancer	135	Mumbrekar et.al. / 2017. ⁸¹
rs25487	XRCC1	DNA repair	Dermatitis	Blood DNA/ NPC	114	Chen et.al / 2017. ⁸²
rs1829346 rs36080650	TUSC7	IncRNA-p53 regulatory network. Apoptosis.	Dermatitis	Blood LncRNA/ NPC	238	Guo et.al. / 2017. ⁸³

rs25487	XRCC1	DNA repair	Acute skin toxicity	Blood DNA/ Rectal cancer	67	Osti et.al. / 2017. ⁸⁴
rs1801320	RAD51	DNA repair	Acute skin toxicity	Blood DNA/ Rectal cancer	67	Osti et.al. / 2017. ⁸⁴
rs3815496 rs1131532	TRAIL/TNF SF10	Radiation induced apoptosis	Dermatitis	Blood DNA/ Breast cancer	113	Baijer et.al / 2016. ⁸⁵
rs1799983	NOS3	ROS metabolism	Acute radiation skin toxicity	Blood DNA/ Breast cancer	80	Córdoba et.al. / 2016. ⁸⁶
rs1799964	TNF	Inflammation	Dermatitis	Blood DNA/ Rectal cancer	356	Zhang et.al. / 2015. ⁸⁷
rs1800734	MLH1	DNA repair	Dermatitis	Blood DNA/ Breast cancer	377	Langhe et.al. / 2014. ⁸⁸
*	GSTM1	Oxidative stress	Acute radiation skin toxicity	Blood DNA/ Breast cancer	59	Borghini et.al. / 2014. ⁸⁹
rs1800469	TGFB1	Cell growth, differentiation and apoptosis	Erythema	Blood DNA/ Breast cancer	83	Raabe et.al. / 2012. 90
rs3790568	IL12RB2	Pro-inflammatory/ immune system/ apoptosis	Dermatitis	Blood DNA/ Breast cancer	156	Isomura et.al. / 2008. 91
rs2253304	ABCA1	Apoptosis, metabolism (efflux of cholesterol to high-density lipoprotein)	Dermatitis	Blood DNA/ Breast cancer	156	Isomura et.al. / 2008. 91

SNPs name was not specified

Table 2: Pathways and biological functions of genes associated with radiotherapy induced acute inflammatory pain.

Pathway	Genes	Number (n)	Percent (%)
DNA damage / DNA repair	XRCC1, XRCC2, XPD, ZNF24, NBN, Ku70, ATM, CHEK1, RAD51C, ERCC2, PMS1, MLH1	12	30 %
Inflammatory/ Immune system	STING1, HLA-DQB1, TNF-α, TNFRSF1A, GHRL, PLA2G2F/ IIF, IFNG, IL12RB2, CD44, TNF	10	25 %
Cell death/ Apoptosis/Autophagy/ Cell cycle	ATG16L2, ATG10, TUSC7, ABCA1, CCND1, TGFB1, TRAIL/TNFSF10	7	17.5 %
Metabolism/ Microenvironment	APEH, EDN1, GSK3β, APC, NOS3, GSTM1	6	15 %
Others	DNAJC18, CCHCR1, TNKS, PTPN3, MAT1A	5	12.5 %

2- Variants associated with radiotherapy induced Neuropathic pain:

Neuropathic pain is one of the common types of pain developed after receiving RT in HNC. Few studies focused on identification of SNPs associated with radiotherapy-induced neuropathic pain. Reyes-Gibby et.al study was the only literature published to identify SNPs associated with neuropathy and neuropathic pain in HNC. 4 variants in 4 genes were identified, associated with radiotherapy induced neuropathic pain. (Table 3)

Table 3: Summary of literature search of variants associated with radiotherapy induced acute neuropathic pain

SNP	Gene	Pathway	Phenotype	Sample/cancer	Number of patients	Author /year
rs10950641	SNX8	Endocytosis, endosomal sorting and signaling. Glutamatergic- receptor- dependent neural plasticity	Neuropathic pain	DNA/ HNC	1,043	Reyes- Gibby et.al. / 2018 ⁹²
rs6796803	KNG1	kinins act as mediators of pain and inflammation	Neuropathic pain	DNA/ HNC	1,043	Reyes- Gibby et.al/2018 ⁹²

rs4775319	RORA	Expression pattern in lamina II of SC, a region for relaying somatosensory signals of touch, temperature and pain	Neuropathic pain	DNA/ HNC	1,043	Reyes- Gibby et.al. / 2018 ⁹²
rs4804217	PCP2	Neuron- specific modulator of intracellular signaling via G proteins	Neuropathic pain	DNA/ HNC	1,043	Reyes- Gibby et.al. / 2018 ⁹²

3- Variants associated with mixed types of radiotherapy induced acute pain:

Our literature search revealed some studies identified SNPs associated with post RT-pain without classification of type of pain, we considered this phenotype as mixed types of pain. 13 variants in 10 genes associated with RT-induced Throat/Neck pain and other mixed types of post RT-pain as main phenotype (Table 4).3 genes (21.4%) are involved in cell death and apoptosis pathways, 3 genes (21.4%) are involved in metabolic and microenvironment processes; EGFL6 gene plays a role in angiogenesis ⁹³, aquaporin gene AQP7 which plays a rule in water transport through waterselective membrane channel ⁹⁴, and PLAUR gene which plays a role in proteolysisindependent signal transduction ⁹⁵. 1 gene are



enriched in neurotransmission/neuropathy pathways or play roles as nociceptors stimuli,1 gene (1%) has a function in DNA damage responses pathway; ATM gene ⁹⁶. (Figure 3, Table 5).

Table 4: Summery of literature search of variants associated with other types of radiotherapy induced acute pain.

SNP	Gene	Pathway	Phenot	ype	Sample	/cancer	Number of patients	Author/year
rs16970540	RFFL	TP53/ Apoptosis	Post pain	RT-	DNA/ cancer	Breast	1112	Lee et.al. / 2019. ⁹⁷
rs4584690 rs7335912	ABCC4/MPR4	Neurotransmitter, transports most prostaglandins (PGs), altered	Post pain	RT-	DNA/ cancer	Breast	1112	Lee et.al. / 2019. ⁹⁷

		inflammatory nociceptive responses				
rs73633565	EGFL6	Angiogenesis	Post RT- pain	DNA/ Breast cancer	1112	Lee et.al. / 2019. 97
rs1800629	TNFα	NF-κβ pathway, (Inflammation)	Neck pain/ throat pain	DNA/ Thyroid cancer	203	Liu et.al. / 2018. 96
rs11212570	АТМ	DNA damage response (DDR)	Throat pain	DNA/ Thyroid cancer	203	Liu et.al. / 2018. 96
rs230493	NF-κβ	Inflammation	Throat pain	DNA/ Thyroid cancer	203	Liu et.al. / 2018. ⁹⁶
rs1800469 rs2241716	TGF-β	Cell growth, cell differentiation, vascular regeneration and apoptosis	Throat pain	DNA/ Thyroid cancer	203	Liu et.al. / 2018. ⁹⁶
rs76608797 rs33386144	AQP7	Water-selective membrane channel	Post RT- pain	DNA/ Bone metastasis	25	Furfari et.al. / 2017. ⁹⁵
rs4760	PLAUR	Proteolysis- independent signal transduction activation effects of U-PA/ cell surface protein	Post RT- pain	DNA/ Bone metastasis	25	Furfari et.al. / 2017. ⁹⁵
rs11545302	ELAC2	TGF-β signaling/ cell growth, cell differentiation, vascular regeneration and apoptosis	Post RT- pain	DNA/ Bone metastasis	25	Furfari et.al. / 2017. ⁹⁵

Table 5: Pathways and biological functions of genes associated with mixed types of radiotherapy induced acute pain.

Pathway	Genes	Number (n)	Percent (%)
Cell death/ Apoptosis	RFFL, TGF-β, ELAC2	3	30%
Metabolisms/ Microenvironment	EGFL6, AQP7, PLAUR	3	30%
Inflammatory/ Immune system	ΤΝFα, NF-κβ	2	20%

Neurotransmission/neuropathy	ABCC4/MPR4	1	10%
DNA damage / DNA repair	ATM	1	10%

Discussion:

Acute pain is a significant toxicity during and after radiotherapy in HNC, resulting in increase in disability risks, increase in morbidity and decrease in the quality of life of these patients. Acute pain control resulting from RT is highly challenging due to the multifactorial clinical, genetic and molecular mechanisms. Understanding the potential mechanisms and the host genetic variability can help in pain prediction, prevention and in decision making for personalized pain management. To date, few studies explore the mechanisms of acute pain in HNC patients receiving RT. Moreover, very few variants have been identified associated with RT-induced acute pain and relevant acute toxicities in HNC. In this systematic review, we studied the different potential mechanisms for acute pain developed during RT in HNC cancer patients.SNPs identified associated with RT-induced acute pain, mucositis and dermatitis in different types of cancers were collected for comprehensive search.

Our review found that DNA damage, DNA repair, cell death and inflammation are essential in inducing inflammatory pain following RT. Variants detected in genes involved in DNA damage response or DNA repair are associated with acute toxicities (mucositis and dermatitis) related to RT. 18 published studies evaluated the association of variants in DNA damage and DNA repair with RT-induced acute toxicities, 6 out of the 18 studies focused on variants in X-Ray Repair Cross Complementing 1 gene (XRCC1) as a DNA repair gene highly associated with radiotherapy toxicity ^{61, 63, 74, 75, 98}. Other variants in DNA damage and repair genes; XRCC2, XPD, ERCC1, ZNF24, NBN, Ku70, ATM, CHEK1, RAD51C, ERCC2, PMS1, MLH1 were associated with RTacute toxicities, these results matched our study of the potential mechanisms of inflammatory pain induced by RT²². Additionally, 11 studies identified variants in genes involved in inflammatory pathways and immune systems including; TNF-α^{60, 96, 99}, STING1¹⁰⁰, HLA-DQB1⁵⁸, TNFRSF1A ⁶⁴, GHRL ⁶⁵, PLA2G2F/ IIF ¹⁰¹, IFNG ⁸⁰, IL12RB2 ⁹¹ and NF-κβ ⁹⁶, these variants were associated with RT-induced inflammatory pain and mixed throat pain. Studies showed that activation of inflammatory and immune cells after RT induces release of inflammatory cytokines and chemokines promoting more cell damage inducing inflammatory pain in addition to activation of nociceptors causing nociceptive pain ^{32, 33, 102-104}. Reyes-Gibby et.al, studied the rule of cytokines in pain activation and sensitization ^{53, 105}. Variants in genes regulating release of pro-inflammatory mediators as cytokines and chemokines are shown here in our review.

Few studies focused on neuropathic pain induced by RT, Reyes-Gibby et.al identified 4 SNPs in 4 genes (SNX8, PCP2, RORA and KNG1) correlated with neuropathy in HNC ⁹². Although substance-P and other neurotransmitters as excitatory amino acids exaggerates pain response ^{53, 106}, no study have identified any variant in Substance-P or other neurotransmitters amino acids correlated with RT-induced pain, more studies are needed to identify the SNPs related to RT-induced neuropathy and neuropathic pain, specially variants in genes involved in neuronal plasticity and neuroinflammatory pathways. Other cell signaling pathways including cell cycle and NF-kB pathway (CCND1) ^{67, 68}, autophagy (ATG16L2, ATG10) ⁶², wnt/β-catenin (APC, GSK3β) ⁷¹ and angiogenesis (EDN1)⁶⁹ regulating genes were associated with RT related acute mucositis and dermatitis.

Studies included in this review, used either candidate gene approach or genome wide association analysis approach (GWAS), and interestingly through GWAS studies collected, we declared

variants in genes involved in different/new pathways other than the common potential mechanisms of RT-induced pain, associated with RT-induced acute pain and toxicities. Sckack et.al conducted GWAS in HNC patients and identified candidate (rs1131769) in DNAJC18 gene regulating a chaperon molecules protecting cellular proteins, significantly associated with oral mucositis (OM) after RT ⁵⁷. Yang et.al did GWAS of NPC patients and identified variant (rs117157809) in Tankyrase (TNKS) gene regulating telomere capping and maintenance of telomerase activity, is significantly associated with RT-induced OM ⁵⁹. Li et.al, identified GWAS risk loci (rs1265081) in CCHCR1 gene regulating cellular process as keratinocyte proliferation, differentiation and EGFR pathways, associated with RT-induced OM in HNC patients ⁵⁸, while Rattay et.al, identified variant (rs12554549) in PTPN gene regulating cell growth, differentiation and oncogenic transformation, associated with RT-induced acute skin ulceration in breast cancer patients ⁷⁸. Genetic variants involved in oxidative stress response and ROS metabolism pathways (e.g. GSTM1 and NOS3) were associated with RT acute skin toxicity in breast cancer patients ^{81, 107}

Although we did a comprehensive review to identify different potential mechanisms, including molecular pathways and genetic variants associated with RT-induced acute pain and relevant acute toxicities, there are limitations in our review. such as we focused on the most common acute toxicities being the common risk of acute pain as oral mucositis and dermatitis, while there are other acute toxicities could be relevant such as dysphagia. We did a comprehensive search covering all types of cancers, since studies focused on HNC were few and we would like to highlight other variants detected in other cancer types to be validated and focused on in future studies. Furthermore, many studies didn't specify the type of pain detected either inflammatory, nociceptive or neuropathic, while they only mentioned post-RT pain or throat pain, we involved these variants under the group of other types/mixed pain. These studies collected, are just association studies, however, mechanistic studies must be done to test the mechanistic effect of these variants on the phenotype development and alteration of the different pathways associated. These identified candidates need further validation through more studies replication. More comprehensive analysis of the other candidates relevant to different types pf pain not associated with cancer or RT, is considered in our future plans.

Our future directions include validating these genetic variants and developing a predictive algorithm for pain prediction and management optimization using genetic candidates identified in out HNC cohort.

Conclusion:

Multiple studies were conducted to identify different variants associated with cancer pain and cancer treatment induced pain. However, few of them focused on radiotherapy induced acute pain which is considered almost the most common acute toxicity following RT. We did a comprehensive literature review to identify the variants and genes that have been previously reported to have association with radiotherapy induced acute pain phenotypes including; mucositis, dermatitis (Inflammatory pain), neuropathic, nociceptive pain and mixed oral/mouth pain. Our review revealed that pain is a complex symptom following RT in OC/OPC patients due to its multifactorial origin and different phenotypes of its representation. DNA damage/ repair, inflammatory pathways, apoptosis, cell death, and neuropathy pathways are the most common pathways behind the development of radiotherapy-related acute toxicities and acute pain. Furthermore, there is a need for a comprehensive understanding of the genetic profile in addition to the clinical and treatment background of those patients who have high risk to develop acute pain following RT and to identify a more standardized algorithm for personalized management of acute RT-induced pain to maintain pain relief during RT and improve patients' outcome and quality of life.

Abbreviations:

HNSCC:	Head and neck squamous cell carcinoma
OC/OPC:	Oral cavity and oropharyngeal cancer
HPV:	Human papilloma virus
RT:	Radiotherapy
QOL:	Quality of life
SSB:	Single strand breaks
DSB:	Double strand breaks
ROS:	Reactive oxygen species
HNC:	Head and neck cancer
NPC:	Nasopharyngeal cancer
IL:	Interleukins
PG:	Prostaglandins
TNF:	Tumor necrosis factors
Gy:	Gray
VEGF:	vascular endothelial growth factor signaling
GABA	γ-aminobutyric acid
NSCLC	Non-Small Cell Lung Cancer
NGF	Nerve growth factor
ATP	Adenosine triphosphate
SNPs	Single nucleotide polymorphisms
DDR	DNA damage response

References:

 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.

2. Kong M, Hong SE, Choi J, Kim Y. Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer. Radiat Oncol J. 2013;31(1):1-11.

3. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-52.

4. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-44.

5. Muzumder S, Srikantia N, Udayashankar AH, Kainthaje PB, John Sebastian MG. Burden of acute toxicities in head-and-neck radiation therapy: A single-institutional experience. South Asian J Cancer. 2019;8(2):120-3.

6. Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module. Head Neck-J Sci Spec. 2007;29(10):923-31.

7. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420-33.

8. Malik A, Sukumar V, Pai A, Mishra A, Nair S, Chaukar D, et al. Emergency Department Visits by Head-and-Neck Cancer Patients. Indian J Palliat Care. 2019;25(4):535-8.

9. Delgado-Guay MO, Kim YJ, Shin SH, Chisholm G, Williams J, Allo J, et al. Avoidable and unavoidable visits to the emergency department among patients with advanced cancer receiving outpatient palliative care. J Pain Symptom Manage. 2015;49(3):497-504.

10. Caterino JM, Adler D, Durham DD, Yeung SJ, Hudson MF, Bastani A, et al. Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments. JAMA Netw Open. 2019;2(3):e190979.

11. Reyes-Gibby CC, Melkonian SC, Hanna EY, Yeung SJ, Lu C, Chambers MS, et al. Cohort study of oncologic emergencies in patients with head and neck cancer. Head Neck. 2017;39(6):1195-204.

12. Shuman AG, Terrell JE, Light E, Wolf GT, Bradford CR, Chepeha D, et al. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(12):1147-54.

13. Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009;19(1):29-34.

14. Ren JL, Rojo RD, Perez JVD, Yeung SJ, Hanna EY, Reyes-Gibby CC. Variations in pain prevalence, severity, and analgesic use by duration of survivorship: a cross-sectional study of 505 post-treatment head and neck cancer survivors. BMC Cancer. 2021;21(1):1304.

15. Smith WH. Prolonged Opioid Dependence Following Post-Operative Head and Neck Radiation Therapy. ASTRO. 2018;102(3).

16. McDermott JD, Eguchi M, Stokes WA, Amini A, Hararah M, Ding D, et al. Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer. Otolaryngol Head Neck Surg. 2019;160(3):409-19.

17. Muzumder S, Nirmala S, Avinash HU, Sebastian MJ, Kainthaje PB. Analgesic and Opioid Use in Pain Associated with Head-and-Neck Radiation Therapy. Indian J Palliat Care. 2018;24(2):176-8.

18. Jairam V, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Netw Open. 2020;3(8):e2013605.

19. Thopan P, Yu L, Brown IG, Tippawan U. Low-Energy Ion-Species-Dependent Induction of DNA Double-Strand Breaks: Ion Energy and Fluence Thresholds. Radiat Res. 2017;188(4):426-32.

20. Van Der Schans GP. Gamma-ray induced double-strand breaks in DNA resulting from randomlyinflicted single-strand breaks: temporal local denaturation, a new radiation phenomenon? Int J Radiat Biol Relat Stud Phys Chem Med. 1978;33(2):105-20.

21. Kim K, McBride WH. Modifying radiation damage. Curr Drug Targets. 2010;11(11):1352-65.

22. Saha S, Woodbine L, Haines J, Coster M, Ricket N, Barazzuol L, et al. Increased apoptosis and DNA double-strand breaks in the embryonic mouse brain in response to very low-dose X-rays but not 50 Hz magnetic fields. J R Soc Interface. 2014;11(100):20140783.

23. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res. 2000;301(1):133-42.

24. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973-9.

25. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res. 2004;162(1):1-19.

26. Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist. 2002;7(2):136-43.

27. Karri J, Lachman L, Hanania A, Marathe A, Singh M, Zacharias N, et al. Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review. Adv Ther. 2021;38(3):1425-46.

28. LAI Y-H. Mechanisms and Models of Pain in Head and Neck Cancer Irradiation. PHD Dissertation, Raleigh, North Carolina, 2020. 2020.

29. Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120(11):3742-4.

30. Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice ASC, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382-6.

31. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739-49.

32. Neta R, Oppenheim JJ. Radioprotection with cytokines--learning from nature to cope with radiation damage. Cancer Cells. 1991;3(10):391-6.

33. Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, et al. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A. 2004;101(8):2452-7.

34. Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res. 2012;178(6):505-23.

35. Muanza TM, Cotrim AP, McAuliffe M, Sowers AL, Baum BJ, Cook JA, et al. Evaluation of radiation-induced oral mucositis by optical coherence tomography. Clin Cancer Res. 2005;11(14):5121-7.

36. Maria OM, Eliopoulos N, Muanza T. Radiation-Induced Oral Mucositis. Front Oncol. 2017;7:89.

37. Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs. 2004;20(1):11-5.

38. Epstein JB, Wilkie DJ, Fischer DJ, Kim YO, Villines D. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009;1:26.

39. Kendroud S, Fitzgerald LA, Murray I, Hanna A. Physiology, Nociceptive Pathways. StatPearls. Treasure Island (FL)2022.

40. Dafny N. Pain Principles. Neuroscience online. 2020.

41. Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience. 1996;70(1):201-9.

42. Abbadie C, Trafton J, Liu H, Mantyh PW, Basbaum AI. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci. 1997;17(20):8049-60.

43. Henry JL, Sessle BJ, Lucier GE, Hu JW. Effects of substance P on nociceptive and non-nociceptive trigeminal brain stem neurons. Pain. 1980;8(1):33-45.

44. Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers - a review. J Med Life. 2014;7(2):121-3.

45. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705-13.

46. IASP. IASP Task Force on Taxonomy . Classification of Chronic Pain. Second. Seattle: IASP Press; 1994. [Google Scholar].

47. Jin S. Role of p53 in Anticancer Drug Treatment- and Radiation-Induced Injury in Normal Small Intestine. Cancer Biol Med. 2012;9(1):1-8.

48. Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, et al. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One. 2017;12(7):e0180396.

49. Gao Y, Sun N, Wang L, Wu Y, Ma L, Hong J, et al. Bioinformatics Analysis Identifies p53 as a Candidate Prognostic Biomarker for Neuropathic Pain. Front Genet. 2018;9:320.

50. Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors. PM R. 2011;3(11):1041-54.

51. Zorina-Lichtenwalter K, Meloto CB, Khoury S, Diatchenko L. Genetic predictors of human chronic pain conditions. Neuroscience. 2016;338:36-62.

52. Mogil JS. Pain genetics: past, present and future. Trends Genet. 2012;28(6):258-66.

53. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol. 2008;9(8):777-85.

54. Lee S, Kerns S, Ostrer H, Rosenstein B, Deasy JO, Oh JH. Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018;101(1):128-35.

55. GeneCards THGD. <u>https://www.genecards.org/</u>.

56. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016;54:1 30 1-1 3.

57. Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM, et al. A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer. 2022.

58. Li Q, Liang Y, Liu Z, Yu C. Associations of GWAS-Identified Risk Loci with Progression, Efficacy and Toxicity of Radiotherapy of Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy. Pharmgenomics Pers Med. 2021;14:1205-10.

59. Yang DW, Wang TM, Zhang JB, Li XZ, He YQ, Xiao RW, et al. Genome-wide association study identifies genetic susceptibility loci and pathways of radiation-induced acute oral mucositis. J Transl Med. 2020;18(1).

60. Mlak R, Powrozek T, Brzozowska A, Homa-Mlak I, Mazurek M, Golebiowski P, et al. The relationship between TNF-alpha gene promoter polymorphism (- 1211 T > C), the plasma concentration of TNF-alpha, and risk of oral mucositis and shortening of overall survival in patients subjected to intensity-modulated radiation therapy due to head and neck cancer. Support Care Cancer. 2020;28(2):531-40.

61. Yang Z, Liu Z. Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer. J Oncol. 2020;2020:3132786.

62. Yang Z, Liu Z. Potentially functional variants of autophagy-related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma. Mol Genet Genomic Med. 2019;7(12):e1030.

63. Ankita Gupta DM, Sushmita Ghoshal & Arnab Pal. XRCC1 (rs25487) polymorphism is associated with severe oral mucositis and poor treatment response after radiotherapy for oropharyngeal carcinoma. Oral Cancer volume 3, pages37–47 (2019). 2019.

64. Brzozowska A, Powrozek T, Homa-Mlak I, Mlak R, Ciesielka M, Golebiowski P, et al. Polymorphism of Promoter Region of TNFRSF1A Gene (-610 T > G) as a Novel Predictive Factor for Radiotherapy Induced Oral Mucositis in HNC Patients. Pathol Oncol Res. 2018;24(1):135-43.

65. Brzozowska A, Homa-Mlak I, Mlak R, Golebiowski P, Mazurek M, Ciesielka M, et al. Polymorphism of regulatory region of GHRL gene (-2531C>T) as a promising predictive factor for radiotherapy-induced oral mucositis in patients with head neck cancer. Head Neck. 2018;40(8):1799-811.

66. Brzozowska A, Mlak R, Homa-Mlak I, Golebiowski P, Mazurek M, Ciesielka M, et al. Polymorphism of regulatory region of APEH gene (c.-521G>C, rs4855883) as a relevant predictive factor for radiotherapy induced oral mucositis and overall survival in head neck cancer patients. Oncotarget. 2018;9(51):29644-53.

67. Guo C, Huang Y, Yu J, Liu L, Gong X, Huang M, et al. The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2017;8(15):25334-44.

68. Wang J, Guo C, Gong X, Ao F, Huang Y, Huang L, et al. The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2017;8(45):78633-41.

69. Ma WL, Liu R, Huang LH, Zou C, Huang J, Wang J, et al. Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma. Clin Exp Pharmacol Physiol. 2017;44(5):539-48.

70. Le Z, Niu X, Chen Y, Ou X, Zhao G, Liu Q, et al. Predictive single nucleotide polymorphism markers for acute oral mucositis in patients with nasopharyngeal carcinoma treated with radiotherapy. Oncotarget. 2017;8(38):63026-37.

71. Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L, et al. Genetic polymorphisms of Wnt/beta-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2016;7(50):82528-37.

72. Venkatesh GH, Manjunath VB, Mumbrekar KD, Negi H, Fernandes DJ, Sharan K, et al. Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One. 2014;9(3):e89079.

73. Ren JH, Dai XF, Yan GL, Jin M, Liu CW, Yang KY, et al. Acute oral mucositis in nasopharyngeal carcinoma patients treated with radiotherapy: association with genetic polymorphism in DNA DSB repair genes. Int J Radiat Biol. 2014;90(3):256-61.

74. Li H, You Y, Lin C, Zheng M, Hong C, Chen J, et al. XRCC1 codon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients. Radiat Oncol. 2013;8:31.

75. Pratesi N, Mangoni M, Mancini I, Paiar F, Simi L, Livi L, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol. 2011;99(3):356-61.

76. Raturi V, Hojo H, Bhatt MLB, Suhel M, Wu CT, Bei Y, et al. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head and Neck. 2020;42(5):1045-56.

77. Lee E, Eum SY, Slifer SH, Martin ER, Takita C, Wright JL, et al. Association Between Polymorphisms in DNA Damage Repair Genes and Radiation Therapy-Induced Early Adverse Skin Reactions in a Breast Cancer Population: A Polygenic Risk Score Approach. Int J Radiat Oncol Biol Phys. 2020;106(5):948-57.

78. Rattay T, Veal CD, Azria D, Chang-Claude J, Davidson S, Dunning A, et al. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients - results from the REQUITE cohort study. Eur J Cancer. 2020;138(Supplement 1):S12.

79. Yang J, Huang Y, Feng Y, Li H, Feng T, Chen J, et al. Associations of genetic variations in mismatch repair genes MSH3 and PMS1 with acute adverse events and survival in patients with rectal cancer receiving postoperative chemoradiotherapy. Cancer Research and Treatment. 2019;51(3):1198-206.

80. Oliva D, Nilsson M, Strandeus M, Andersson BA, Sharp L, Laytragoon-Lewin N, et al. Individual Genetic Variation Might Predict Acute Skin Reactions in Women Undergoing Adjuvant Breast Cancer Radiotherapy. Anticancer Res. 2018;38(12):6763-70.

81. Mumbrekar KD, Bola Sadashiva SR, Kabekkodu SP, Fernandes DJ, Vadhiraja BM, Suga T, et al. Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):118-27.

82. Chen H, Wu M, Li G, Hua L, Chen S, Huang H. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore). 2017;96(44):e8202.

83. Guo Z, Wang Y, Zhao Y, Jin Y, An L, Wu B, et al. Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients. Oncotarget. 2017;8(37):62286-97.

84. Osti MF, Nicosia L, Agolli L, Gentile G, Falco T, Bracci S, et al. Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. Am J Clin Oncol. 2017;40(6):535-42.

85. Baijer J, Dechamps N, Perdry H, Morales P, Kerns S, Vasilescu A, et al. TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis. Oncotarget. 2016;7(16):21416-27.

86. Cordoba EE, Abba MC, Lacunza E, Fernande E, Guerci AM. Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy. Cancer Res. 2016;48(3):948-54.

87. Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y, et al. TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated with Chemoradiotherapy. Medicine (United States). 2015;94(45):e1955.

88. De Langhe S, Mulliez T, Veldeman L, Remouchamps V, van Greveling A, Gilsoul M, et al. Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer. 2014;14:711.

89. Borghini A, Vecoli C, Mercuri A, Petruzzelli MF, D'Errico MP, Portaluri M, et al. Genetic risk score and acute skin toxicity after breast radiation therapy. Cancer Biotherapy and Radiopharmaceuticals. 2014;29(7):267-72.

90. Raabe A, Derda K, Reuther S, Szymczak S, Borgmann K, Hoeller U, et al. Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol. 2012;7:65.

91. Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, et al. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res. 2008;14(20):6683-9.

92. Reyes-Gibby CC, Wang J, Yeung SJ, Chaftari P, Yu RK, Hanna EY, et al. Genome-wide association study identifies genes associated with neuropathy in patients with head and neck cancer. Sci Rep. 2018;8(1):8789.

93. Lee E, Takita C, Wright JL, Slifer SH, Martin ER, Urbanic JJ, et al. Genome-wide enriched pathway analysis of acute post-radiotherapy pain in breast cancer patients: a prospective cohort study. Hum Genomics. 2019;13.

94. King LS, Kozono D, Agre P. From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol. 2004;5(9):687-98.

95. Furfari A, Wan BA, Ding K, Wong A, Zhu L, Bezjak A, et al. Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases. Ann Palliat Med. 2017;6(Suppl 2):S248-S56.

96. Liu J, Tang X, Shi F, Li C, Zhang K, Liu J, et al. Genetic polymorphism contributes to (131)I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. Pharmacogenomics. 2018;19(17):1335-44.

97. Lee E, Takita C, Wright JL, Slifer SH, Martin ER, Urbanic JJ, et al. Genome-wide enriched pathway analysis of acute post-radiotherapy pain in breast cancer patients: a prospective cohort study. Hum Genomics. 2019;13(1):28.

98. Raturi V, Hojo H, Bhatt MLB, Suhel M, Wu CT, Bei Y, et al. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head Neck. 2020;42(5):1045-56.

99. Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y, et al. TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. Medicine (Baltimore). 2015;94(45):e1955.

100. Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM, et al. A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. Br J Cancer. 2022.

101. Rattay T, Veal CD, Azria D, Chang-Claude J, Davidson S, Dunning A, et al. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients - results from the REQUITE cohort study. Eur J Cancer. 2020;138:S12-S.

102. Neta R, Oppenheim JJ. Radioprotection with cytokines: a clarification of terminology. Cancer Cells. 1991;3(11):457.

103. Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I--mechanisms. J Dent Res. 2007;86(6):491-505.

104. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II--clinical perspectives and management. J Dent Res. 2007;86(6):506-18.

105. Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, et al. The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3262-7.

106. Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behav Immun. 2003;17 Suppl 1:S125-31.

107. Cordoba EE, Abba MC, Lacunza E, Fernande E, Guerci AM. Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy. Cancer Res Treat. 2016;48(3):948-54.